Drug Discovery World features Dave Cole discussing challenges and advances in re-engineering oncolytic immunotherapy

Drug Discovery World features Dave Cole, Head of Research at Accession Therapeutics, discussing how oncolytic immunotherapy is being re‑engineered to overcome limitations in systemic delivery and immune engagement. He explains the rationale behind a replicating viral approach, including Accession’s TROCEPT platform, designed to deliver targeted immunotherapies directly within tumours. Dave also highlights the biological challenges tumours present, such as immune exclusion and evasion mechanisms, and how advances in viral design and immunotherapy integration could help increase response rates and therapeutic impact across a broader range of cancers.

Read the full Drug Discovery World article here >